{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:34:34Z","timestamp":1794108874248,"version":"4.8.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01238-4","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T12:17:48Z","timestamp":1749385068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["U.S. substance use harm reduction efforts: a review of the current state of policy, policy barriers, and recommendations"],"prefix":"10.1186","volume":"22","author":[{"given":"Bailey E.","family":"Pridgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Bontemps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey R.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen F.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Cropsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"key":"1238_CR1","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health [Internet]. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2024 July. Available from: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt47095\/National%20Report\/National%20Report\/2023-nsduh-annual-national.pdf. Accessed 1 Oct 2024."},{"key":"1238_CR2","unstructured":"Centers for Disease Control and Prevention. Understanding drug overdoses and deaths[Internet].\u00a0Atlanta, GA: Centers for Disease Control and Prevention;2023 May 8. Available from: https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html. Accessed 22 May 2023."},{"key":"1238_CR3","doi-asserted-by":"publisher","unstructured":"Ahmad FB, Cisewski JA, Rossen L. M., Sutton P. Provisional drug overdose death counts [Internet]. Hyattsville, MD: National Center for Health Statistics; 2024.\u00a0Available from: https:\/\/doi.org\/10.15620\/cdc\/20250305008. Accessed 16 April 2024.","DOI":"10.15620\/cdc\/20250305008"},{"key":"1238_CR4","unstructured":"State Unintentional Drug Overdose Reporting System (SUDORS) Final Data. [Internet]. Atlanta, GA: USDepartment of Health and Human Services, CDC; 2024 December 12[cited].\u00a0Available from: https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/sudors-dashboard-fatal-overdose-data.html. Accessed 24 March 2025."},{"issue":"3","key":"1238_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s40429-023-00506-2","volume":"10","author":"C Valasek","year":"2023","unstructured":"Valasek C, Bazzi AR. Intersectionality and structural drivers of fatal overdose disparities in the United States: a narrative review. Curr Addict Rep. 2023;10(3):432\u201340.","journal-title":"Curr Addict Rep"},{"key":"1238_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111649","author":"MK Smith","year":"2024","unstructured":"Smith MK, Planalp C, Bennis SL, Stately A, Nelson I, Martin J, et al. Widening racial disparities in the US overdose epidemic. Am J Prev Med. 2024. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111649.","journal-title":"Am J Prev Med."},{"issue":"5","key":"1238_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1176\/appi.ajp.20230917","volume":"181","author":"JR Friedman","year":"2024","unstructured":"Friedman JR, Nguemeni Tiako MJ, Hansen H. Understanding and addressing widening racial inequalities in drug overdose. Am J Psychiatry. 2024;181(5):381\u201390.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1238_CR8","doi-asserted-by":"publisher","first-page":"e0307688","DOI":"10.1371\/journal.pone.0307688","volume":"20","author":"CE Zachry","year":"2025","unstructured":"Zachry CE, O\u2019Brien RP, Clark KA, Ding ML, Blosnich JR. Mortality among sexual and gender minority populations: a systematic review. PLoS ONE. 2025;20(2):e0307688.","journal-title":"PLoS ONE"},{"issue":"1","key":"1238_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/lgbt.2022.0036","volume":"10","author":"MM Paschen-Wolff","year":"2023","unstructured":"Paschen-Wolff MM, Kidd JD, Paine EA. The state of the research on opioid outcomes among lesbian, gay, bisexual, transgender, queer, and other sexuality-and gender-diverse populations: a scoping review. LGBT health. 2023;10(1):1\u201317.","journal-title":"LGBT health"},{"issue":"6","key":"1238_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","volume":"70","author":"CL Mattson","year":"2021","unstructured":"Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019. Morb Mortal Wkly Rep. 2021;70(6):202.","journal-title":"Morb Mortal Wkly Rep"},{"key":"1238_CR11","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm675152e1","author":"L Scholl","year":"2019","unstructured":"Scholl L. Drug and opioid-involved overdose deaths\u2014United States, 2013\u20132017. MMWR Morb Mortal Wkly Report. 2019. https:\/\/doi.org\/10.15585\/mmwr.mm675152e1.","journal-title":"MMWR Morb Mortal Wkly Report."},{"issue":"48","key":"1238_CR12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.15585\/mmwr.mm7348a2","volume":"73","author":"LJ Tanz","year":"2024","unstructured":"Tanz LJ, Stewart A, Gladden RM, Ko JY, Owens L, O\u2019Donnell J. Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths\u2014United States, 2021\u20132024. Morb Mortal Wkly Rep. 2024;73(48):1099.","journal-title":"Morb Mortal Wkly Rep"},{"key":"1238_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.06.010","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int J Drug Policy. 2017. https:\/\/doi.org\/10.1016\/j.drugpo.2017.06.010.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1238_CR14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/add.14878","volume":"115","author":"B Hoots","year":"2020","unstructured":"Hoots B, Vivolo-Kantor A, Seth P. The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States. Addiction. 2020;115(5):946\u201358.","journal-title":"Addiction"},{"key":"1238_CR15","unstructured":"Centers for Disease Control and Prevention. Drug overdose deaths [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; Date unknown [updated 2024 August 2]. Available from: https:\/\/www.cdc.gov\/nchs\/hus\/topics\/drug-overdose-deaths.htm. Accessed 28 May 2025."},{"key":"1238_CR16","doi-asserted-by":"crossref","unstructured":"Spencer MR, Mini\u00f1o AM, Garnett M. Co-involvement of Opioids in Drug Overdose Deaths Involving Cocaine and Psychostimulants, 2011\u20132021 [Internet]. Washington D.C.: US Department of Health & Human Services, Centers for Disease Control and \u2026; 2023 July [cited 2024 April 29]. Available from: https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db474.htm.","DOI":"10.15620\/cdc:129733"},{"key":"1238_CR17","doi-asserted-by":"publisher","first-page":"108350","DOI":"10.1016\/j.drugalcdep.2020.108350","volume":"218","author":"C Florence","year":"2021","unstructured":"Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:108350.","journal-title":"Drug Alcohol Depend"},{"key":"1238_CR18","unstructured":"The White House. The Staggering Cost of the Illicit Opioid Epidemic in the United States [Internet]. 2025 Mar 26 [cited 2025 April 14]. Available from: https:\/\/www.whitehouse.gov\/articles\/2025\/03\/the-staggering-cost-of-the-illicit-opioid-epidemic-in-the-united-states\/."},{"issue":"1","key":"1238_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/cid\/ciac543","volume":"76","author":"H Bradley","year":"2023","unstructured":"Bradley H, Hall EW, Asher A, Furukawa NW, Jones CM, Shealey J, et al. Estimated number of people who inject drugs in the United States. Clin Infect Dis. 2023;76(1):96\u2013102.","journal-title":"Clin Infect Dis"},{"key":"1238_CR20","doi-asserted-by":"crossref","unstructured":"Leyva Y, Page K, Shiboski S, Hahn JA, Evans J, Erhardt E, editors. Per-contact infectivity of hepatitis C virus acquisition in association with receptive needle sharing exposures in a prospective cohort of young adult people who inject drugs in San Francisco, California. Open Forum Infectious Diseases; 2020: Oxford University Press US.","DOI":"10.1093\/ofid\/ofaa092"},{"issue":"4","key":"1238_CR21","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1097\/QAI.0000000000002062","volume":"81","author":"LJ Ball","year":"2019","unstructured":"Ball LJ, Puka K, Speechley M, Wong R, Hallam B, Wiener JC, et al. Sharing of injection drug preparation equipment is associated with HIV infection: a cross-sectional study. JAIDS J Acquir Immune Defic Syndr. 2019;81(4):e99\u2013103.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"1238_CR22","unstructured":"National Academies of Sciences Engineering and Medicine. Opportunities to improve opioid use disorder and infectious disease services: integrating responses to a dual epidemic[Internet]. Washington, D.C.: National Academies of Sciences, Engineering, and Medicine; 2020 [cited 2024 May 29]. Available from:\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK555809\/."},{"key":"1238_CR23","unstructured":"Centers for Disease Control and Prevention. Hepatitis C Surveillance Report 2020[Internet]. Atlanta, GA: Centers for Disease Control and Prevention; Date unknown [updated 2022 August 19]. Available from: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2020surveillance\/hepatitis-c.htm#print. Accessed 1 May 2023."},{"key":"1238_CR24","unstructured":"Office of Infectious Disease and HIV\/AIDS Policy. Viral hepatitis in the United States: data and trends 2016 [Internet].\u00a0Washington D.C.: U.S. Department of Health and Human Services; Date unknown [updated 2016 June 7].Available from: https:\/\/www.hhs.gov\/hepatitis\/learn-about-viral-hepatitis\/data-and-trends\/index.html#:~:text=850%2C000%20people%20in%20the%20U.S.,or%20as%20low%20as%20730%2C000. Accessed 13 Feb 2024."},{"issue":"3","key":"1238_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jhepr.2019.06.006","volume":"1","author":"EC Verna","year":"2019","unstructured":"Verna EC, Schluger A, Brown RS Jr. Opioid epidemic and liver disease. Jhep Reports. 2019;1(3):240\u201355.","journal-title":"Jhep Reports"},{"issue":"3","key":"1238_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.cld.2017.03.012","volume":"21","author":"M Stepanova","year":"2017","unstructured":"Stepanova M, Younossi ZM. Economic burden of hepatitis C infection. Clin Liver Dis. 2017;21(3):579\u201394.","journal-title":"Clin Liver Dis"},{"key":"1238_CR27","unstructured":"Centers for Disease Control and Prevention. HIV Surveillance Report[Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2022 May [cited 2023 May 8]. Available from: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2020surveillance\/hepatitis-c.htm#print."},{"key":"1238_CR28","unstructured":"Centers for Disease Control and Prevention. HIV Infection risk, prevention, and testing behaviors among persons who inject drugs: National HIV Behavioral Surveillance: injection drug use, 23 U.S. cities, 2018 [Internet].\u00a0Atlanta, GA: Centers for Disease Control and Prevention; 2020 February [cited 2023 May 8]. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/106349."},{"issue":"5","key":"1238_CR29","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s10461-020-02988-x","volume":"25","author":"CB Mistler","year":"2021","unstructured":"Mistler CB, Copenhaver MM, Shrestha R. The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: a systematic review. AIDS Behav. 2021;25(5):1490\u2013506.","journal-title":"AIDS Behav"},{"issue":"7","key":"1238_CR30","doi-asserted-by":"publisher","first-page":"e2221346","DOI":"10.1001\/jamanetworkopen.2022.21346","volume":"5","author":"CG Streed Jr","year":"2022","unstructured":"Streed CG Jr, Morgan JR, Gai MJ, Larochelle MR, Paasche-Orlow MK, Taylor JL. Prevalence of HIV preexposure prophylaxis prescribing among persons with commercial insurance and likely injection drug use. JAMA Netw Open. 2022;5(7):e2221346.","journal-title":"JAMA Netw Open."},{"issue":"4","key":"1238_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/OLQ.0000000000001366","volume":"48","author":"A Bingham","year":"2021","unstructured":"Bingham A, Shrestha RK, Khurana N, Jacobson EU, Farnham PG. Estimated lifetime HIV\u2013related medical costs in the United States. Sex Transm Dis. 2021;48(4):299\u2013304.","journal-title":"Sex Transm Dis"},{"issue":"6","key":"1238_CR32","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/j.jval.2024.03.570","volume":"27","author":"M Islam","year":"2024","unstructured":"Islam M, Chesson H, Hutchinson A, Shrestha R, Song R, Viguerie A, et al. EE271 lifetime productivity loss due to HIV mortality in the United States. Value in Health. 2024;27(6):S107.","journal-title":"Value in Health"},{"issue":"1","key":"1238_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12954-022-00624-6","volume":"19","author":"A Hrycko","year":"2022","unstructured":"Hrycko A, Mateu-Gelabert P, Ciervo C, Linn-Walton R, Eckhardt B. Severe bacterial infections in people who inject drugs: the role of injection-related tissue damage. Harm Reduct J. 2022;19(1):41.","journal-title":"Harm Reduct J"},{"key":"1238_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2016.11.029","volume":"171","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39\u201349.","journal-title":"Drug Alcohol Depend"},{"key":"1238_CR35","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s10900-017-0458-9","volume":"43","author":"MG Collier","year":"2018","unstructured":"Collier MG, Doshani M, Asher A. Using population based hospitalization data to monitor increases in conditions causing morbidity among persons who inject drugs. J Commun Health. 2018;43:598\u2013603.","journal-title":"J Commun Health"},{"key":"1238_CR36","unstructured":"Infectious Diseases Society of America , HIV Medicine Association, and Pediatric Infectious Diseases Society. Infectious diseases and opioid use disorder: policy issues and recommendations [Internet]. Arlington, VA: Infectious Diseases Society of America; 2018 March [cited 2024 September 5]. Available from: https:\/\/www.idsociety.org\/globalassets\/idsa\/news-and-publication\/press-releases\/2018\/id-and-the-opioid-epidemic-policy-brief_3-19-2018-updated.pdf."},{"key":"1238_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa432","author":"A Levitt","year":"2020","unstructured":"Levitt A, Mermin J, Jones CM, See I, Butler JC. Infectious diseases and injection drug use: public health burden and response. J Infect Dis. 2020. https:\/\/doi.org\/10.1093\/infdis\/jiaa432.","journal-title":"J Infect Dis."},{"issue":"Suppl 5","key":"1238_CR38","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1093\/infdis\/jiaa149","volume":"222","author":"I See","year":"2020","unstructured":"See I, Gokhale RH, Geller A, Lovegrove M, Schranz A, Fleischauer A, et al. National public health burden estimates of endocarditis and skin and soft-tissue infections related to injection drug use: a review. J Infect Dis. 2020;222(Suppl 5):S429\u201336.","journal-title":"J Infect Dis"},{"issue":"3","key":"1238_CR39","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/sw\/49.3.353","volume":"49","author":"SA MacMaster","year":"2004","unstructured":"MacMaster SA. Harm reduction: a new perspective on substance abuse services. Soc Work. 2004;49(3):356\u201363.","journal-title":"Soc Work"},{"issue":"6","key":"1238_CR40","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0306-4603(96)00042-1","volume":"21","author":"GA Marlatt","year":"1996","unstructured":"Marlatt GA. Harm reduction: Come as you are. Addict Behav. 1996;21(6):779\u201388.","journal-title":"Addict Behav"},{"key":"1238_CR41","unstructured":"Kreit A. Controlled Substances: Crime, Regulation, and Policy [Internet]. 1st ed. Durham, NC: Carolina Academic Press; 2013 [cited 2024 May 17]. p. 19\u2013125. Carolina Academic Press; 2013."},{"issue":"2","key":"1238_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/wps.20428","volume":"16","author":"ND Volkow","year":"2017","unstructured":"Volkow ND, Poznyak V, Saxena S, Gerra G. Drug use disorders: impact of a public health rather than a criminal justice approach. World Psychiatry. 2017;16(2):213\u20134.","journal-title":"World Psychiatry"},{"key":"1238_CR43","unstructured":"Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2016 Data on Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017 August 3 [cited 2025 March 28]. Available from: https:\/\/www.samhsa.gov\/data\/report\/national-survey-substance-abuse-treatment-facilities-n-ssats-2016-data-substance-abuse."},{"issue":"4","key":"1238_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.15288\/jsad.2020.81.405","volume":"81","author":"H Rosenberg","year":"2020","unstructured":"Rosenberg H, Grant J, Davis AK. Acceptance of non-abstinence as an outcome goal for individuals diagnosed with substance use disorders: A narrative review of published research. J Stud Alcohol Drugs. 2020;81(4):405\u201315.","journal-title":"J Stud Alcohol Drugs"},{"key":"1238_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-017-0196-4","volume":"14","author":"M Hawk","year":"2017","unstructured":"Hawk M, Coulter RW, Egan JE, Fisk S, Reuel Friedman M, Tula M, et al. Harm reduction principles for healthcare settings. Harm Reduct J. 2017;14:1\u20139.","journal-title":"Harm Reduct J"},{"issue":"9","key":"1238_CR46","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1007\/s11606-024-08693-y","volume":"39","author":"M Hawk","year":"2024","unstructured":"Hawk M, Kay ES, Jawa R. Relational harm reduction for internists: a call to action. J Gen Intern Med. 2024;39(9):1746\u20138.","journal-title":"J Gen Intern Med"},{"key":"1238_CR47","unstructured":"Substance Abuse and Mental Health Services Administration. Harm Reduction Framework[Internet]. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2023 [cited 2024 April 29]. Available from: https:\/\/www.samhsa.gov\/sites\/default\/files\/harm-reduction-framework.pdf."},{"key":"1238_CR48","unstructured":"National Peer Council. Peers Speak Out: Priority Outcomes for Substance Use Treatment and Services[Internet]. 2021 [cited 2024 May 1]. Available from: https:\/\/communitycatalyst.org\/wp-content\/uploads\/2023\/02\/Peers-Speak-Out.pdf."},{"key":"1238_CR49","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.addbeh.2015.02.001","volume":"45","author":"SE Collins","year":"2015","unstructured":"Collins SE, Grazioli VS, Torres NI, Taylor EM, Jones CB, Hoffman GE, et al. Qualitatively and quantitatively evaluating harm-reduction goal setting among chronically homeless individuals with alcohol dependence. Addict Behav. 2015;45:184\u201390.","journal-title":"Addict Behav"},{"issue":"7","key":"1238_CR50","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/ajad.12263","volume":"24","author":"BE Lozano","year":"2015","unstructured":"Lozano BE, Gros DF, Killeen T, Jaconis M, Beylotte FM III, Boyd S, et al. To reduce or abstain? Substance use goals in the treatment of veterans with substance use disorders and comorbid PTSD. Am J Addict. 2015;24(7):578\u201381.","journal-title":"Am J Addict"},{"key":"1238_CR51","doi-asserted-by":"publisher","first-page":"102110","DOI":"10.1016\/j.cpr.2021.102110","volume":"91","author":"CE Paquette","year":"2022","unstructured":"Paquette CE, Daughters SB, Witkiewitz K. Expanding the continuum of substance use disorder treatment: Nonabstinence approaches. Clin Psychol Rev. 2022;91:102110.","journal-title":"Clin Psychol Rev"},{"issue":"2","key":"1238_CR52","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.jsat.2004.10.013","volume":"28","author":"ML Dennis","year":"2005","unstructured":"Dennis ML, Scott CK, Funk R, Foss MA. The duration and correlates of addiction and treatment careers. J Subst Abuse Treat. 2005;28(2):S51\u201362.","journal-title":"J Subst Abuse Treat"},{"key":"1238_CR53","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.91.12s1.6.x","author":"WR Miller","year":"1996","unstructured":"Miller WR. What is a relapse? Fifty ways to leave the wagon. Addiction. 1996. https:\/\/doi.org\/10.1046\/j.1360-0443.91.12s1.6.x.","journal-title":"Addiction."},{"key":"1238_CR54","unstructured":"Marlatt GA, Donovan DM. Relapse Prevention for Alcohol and Drug Problems. In: Relapse prevention: Maintenance strategies in the treatment of addictive behaviors. New York, NY: Guilford Press; 2005 [cited 2024 May 17]. p. 1\u201344."},{"issue":"2","key":"1238_CR55","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/alcalc\/agq005","volume":"45","author":"SJ Adamson","year":"2010","unstructured":"Adamson SJ, Heather N, Morton V, Raistrick D. Initial preference for drinking goal in the treatment of alcohol problems: II. Treat Outcomes Alcohol Alcohol. 2010;45(2):136\u201342.","journal-title":"Treat Outcomes Alcohol Alcohol"},{"issue":"1","key":"1238_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1037\/a0030886","volume":"81","author":"S Bujarski","year":"2013","unstructured":"Bujarski S, O\u2019Malley SS, Lunny K, Ray LA. The effects of drinking goal on treatment outcome for alcoholism. J Consult Clin Psychol. 2013;81(1):13.","journal-title":"J Consult Clin Psychol"},{"key":"1238_CR57","first-page":"1","volume":"1000","author":"D Riley","year":"2000","unstructured":"Riley D, O\u2019Hare P. Harm reduction: History, definition, and practice. Harm Reduct: Natl internat Perspect. 2000;1000:1\u201326.","journal-title":"Harm Reduct: Natl internat Perspect"},{"issue":"2","key":"1238_CR58","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/15360288.2015.1037521","volume":"29","author":"AB Kanouse","year":"2015","unstructured":"Kanouse AB, Compton P. The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response. J Pain Palliat Care Pharmacother. 2015;29(2):102\u201314.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"1238_CR59","unstructured":"Azar A, Giroir A. Strategy to combat opioid abuse, misuse, and overdose: A framework based on the five-point strategy[Internet]. Washington, DC: US Department of Health and Human Services ; 2018 [cited 2024 October 10]. Available from: https:\/\/health.maryland.gov\/pophealth\/Documents\/Local%20Health%20Department%20Billing%20Manual\/PDF%20Manual\/Section%20IV\/Opioid%20Five%20Point%20Strategy%20-%2020180917-508%20Compliant.pdf."},{"key":"1238_CR60","unstructured":"Centers for Disease Control and Prevention. Drug Overdose Deaths Rise, Disparities Widen [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; Date unknown [updated 2022 July 19]. Available from: https:\/\/www.cdc.gov\/vitalsigns\/overdose-death-disparities\/. Accessed 1 April 2025."},{"key":"1238_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","journal-title":"Cochrane Database Syst Rev."},{"key":"1238_CR62","unstructured":"Centers for Disease Control and Prevention. Funding for Syringe Services Programs [Internet].\u00a0Atlanta, GA: Centers for Disease Control and Prevention; Date unknown [updated 2024 February 8]. Available from: https:\/\/www.cdc.gov\/syringe-services-programs\/php\/funding\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/ssp\/ssp-funding.html. Accessed 28 May 2025."},{"key":"1238_CR63","doi-asserted-by":"publisher","DOI":"10.1177\/0033354920921817","author":"MH Fern\u00e1ndez-Vi\u00f1a","year":"2020","unstructured":"Fern\u00e1ndez-Vi\u00f1a MH, Prood NE, Herpolsheimer A, Waimberg J, Burris S. State laws governing syringe services programs and participant syringe possession, 2014\u20132019. Public Health Rep. 2020. https:\/\/doi.org\/10.1177\/0033354920921817.","journal-title":"Public Health Rep."},{"key":"1238_CR64","unstructured":"Legislative Analysis and Public Policy Association. Syringe Services Programs: Summary of State Laws\u00a0[Internet]. Washington D.C.: Legislative Analysis and Public Policy Association; 2025 April [cited 2025 April 15]. Available from: https:\/\/legislativeanalysis.org\/wp-content\/uploads\/2025\/04\/Syringe-Services-Programs-Summary-of-State-Laws.pdf."},{"key":"1238_CR65","unstructured":"National Institute on Drug Abuse. Medications for Opioid Use Disorder [Internet]. Bethesda, MD: National Institute on Drug Abuse; Date unknown [updated 2025 March]. Available from: https:\/\/nida.nih.gov\/research-topics\/medications-opioid-use-disorder. Accessed 9 Dec 2023."},{"issue":"2","key":"1238_CR66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63\u201375.","journal-title":"Harv Rev Psychiatry"},{"issue":"3","key":"1238_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137\u201345.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1238_CR68","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo","year":"2021","unstructured":"Santo T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(9):979\u201393.","journal-title":"JAMA Psychiat"},{"key":"1238_CR69","doi-asserted-by":"publisher","first-page":"109445","DOI":"10.1016\/j.drugalcdep.2022.109445","volume":"235","author":"OK Golan","year":"2022","unstructured":"Golan OK, Totaram R, Perry E, Fortson K, Rivera-Atilano R, Entress R, et al. Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder. Drug Alcohol Depend. 2022;235:109445.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1238_CR70","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/00952990701523698","volume":"33","author":"AM Ponizovsky","year":"2007","unstructured":"Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse. 2007;33(5):631\u201342.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"7","key":"1238_CR71","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","volume":"113","author":"BP Jarvis","year":"2018","unstructured":"Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188\u2013209.","journal-title":"Addiction"},{"key":"1238_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001333.pub3","author":"S Minozzi","year":"2011","unstructured":"Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011. https:\/\/doi.org\/10.1002\/14651858.CD001333.pub3.","journal-title":"Cochrane Database Syst Rev."},{"key":"1238_CR73","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejphar.2018.08.007","volume":"836","author":"MC Blanco-Gand\u00eda","year":"2018","unstructured":"Blanco-Gand\u00eda MC, Rodr\u00edguez-Arias M. Pharmacological treatments for opiate and alcohol addiction: a historical perspective of the last 50 years. Eur J Pharmacol. 2018;836:89\u2013101.","journal-title":"Eur J Pharmacol"},{"issue":"10118","key":"1238_CR74","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. The Lancet. 2018;391(10118):309\u201318.","journal-title":"The Lancet"},{"key":"1238_CR75","unstructured":"Food and Drug Administration. FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug [press release]. Silver Spring, MD: The Office of Prescription Drug Promotion (OPDP); 2019 December 11 [cited 2024 October 3]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-issues-warning-letter-not-including-most-serious-risks-advertisement-medication-assisted-treatment-drug."},{"key":"1238_CR76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","volume":"200","author":"JR Morgan","year":"2019","unstructured":"Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019;200:34\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"1238_CR77","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drugpo.2017.05.039","volume":"46","author":"E Kelty","year":"2017","unstructured":"Kelty E, Hulse G. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone. Int J Drug Policy. 2017;46:54\u201360.","journal-title":"Int J Drug Policy"},{"key":"1238_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab289","author":"KF McNamara","year":"2021","unstructured":"McNamara KF, Biondi BE, Hern\u00e1ndez-Ram\u00edrez RU, Taweh N, Grimshaw AA, Springer SA. A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. Open Forum Infect Dis. 2021. https:\/\/doi.org\/10.1093\/ofid\/ofab289.","journal-title":"Open Forum Infect Dis."},{"issue":"2","key":"1238_CR79","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1176\/appi.ps.201300235","volume":"65","author":"CA Fullerton","year":"2014","unstructured":"Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65(2):146\u201357.","journal-title":"Psychiatr Serv"},{"key":"1238_CR80","first-page":"e1229","volume":"2","author":"P Karki","year":"2016","unstructured":"Karki P, Shrestha R, Huedo-Medina TB, Copenhaver M. The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: a systematic review. Evid Based Med Public Health. 2016;2:e1229.","journal-title":"Evid Based Med Public Health"},{"issue":"3","key":"1238_CR81","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/QAI.0000000000000165","volume":"66","author":"GE Woody","year":"2014","unstructured":"Woody GE, Bruce D, Korthuis PT, Chhatre S, Poole S, Hillhouse M, et al. HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial. J Acquir Immune Defic Syndr. 2014;66(3):288\u201393.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"1238_CR82","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/add.14012","volume":"113","author":"L Platt","year":"2018","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545\u201363.","journal-title":"Addiction"},{"issue":"7","key":"1238_CR83","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","volume":"78","author":"M Fairley","year":"2021","unstructured":"Fairley M, Humphreys K, Joyce VR, Bounthavong M, Trafton J, Combs A, et al. Cost-effectiveness of treatments for opioid use disorder. JAMA Psychiat. 2021;78(7):767\u201377.","journal-title":"JAMA Psychiat"},{"key":"1238_CR84","unstructured":"Substance Abuse and Mental Health Services Administration. Waiver Elimination (MAT Act) [Internet]. Rockville, MD: Substance Abuse and Mental Health Services Administration; Date unknown [updated 2024 November 6]. Available from: https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/waiver-elimination-mat-act. Accessed 17 April 2025."},{"key":"1238_CR85","unstructured":"Platt E, Murray CM, Herpolsheimer A, Larsen J. Buprenorphine Prescribing Requirements and Limitations. [Internet]. Philadelphia, PA: Temple University Beasley School of Law Center for Public Health Law Research; 2025 March [cited 2025 April 3]. Available from: https:\/\/phlr.temple.edu\/sites\/phlr\/files\/documents\/VS%20Buprenorphine%20Policy%20Brief_March2025_final.pdf."},{"key":"1238_CR86","unstructured":"Singer JA, Hamilton S. Expand Access to Methadone Treatment (Policy Analysis 960)[Internet]. Washington, D.C.: Cato Institute; 2023 September 7 [cited 2024 September 23]. Available from: https:\/\/www.cato.org\/sites\/cato.org\/files\/2023-08\/policy-analysis-960.pdf."},{"key":"1238_CR87","doi-asserted-by":"publisher","first-page":"104487","DOI":"10.1016\/j.drugpo.2024.104487","volume":"129","author":"H Englander","year":"2024","unstructured":"Englander H, Chappuy M, Krawczyck N, Bratberg J, Potee R, Jauffret-Roustide M, et al. Comparing methadone policy and practice in France and the US: implications for US policy reform. Int J Drug Policy. 2024;129:104487.","journal-title":"Int J Drug Policy"},{"key":"1238_CR88","unstructured":"The Pew Charitable Trusts. New Federal Rules Cannot Improve Methadone Delivery Without State Actions[Internet]. Philadelphia, PA: The Pew Charitable Trusts; 2024 February 21 [updated 2024 May 9]. Available from: https:\/\/www.pew.org\/en\/research-and-analysis\/articles\/2024\/02\/21\/new-federal-rules-cannot-improve-methadone-delivery-without-state-actions. Accessed 27 Sept 2024."},{"key":"1238_CR89","unstructured":"89 FR 7528, (2024)."},{"key":"1238_CR90","unstructured":"The Pew Charitable Trusts. Overview of Opioid Treatment Program Regulations by State. [Internet]. Philadelphia, PA: The Pew Charitable Trusts; 2022 September 19 [cited 6 October 2024]. Available from: https:\/\/www.pew.org\/en\/research-and-analysis\/issue-briefs\/2022\/09\/overview-of-opioid-treatment-program-regulations-by-state."},{"key":"1238_CR91","unstructured":"Substance Abuse and Mental Health Services Administration. Methadone Take-Home Flexibilities Extension Guidance 2024 [Internet].\u00a0Rockville, MD: Substance Abuse and Mental Health Services Administration; Date unknown [updated 2024 November 6]. Available from: https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines\/methadone-guidance. Accessed 17 April 2025."},{"key":"1238_CR92","unstructured":"Temple University Center for Public Health Law Research. Commercial Insurance and Medicaid Coverage of Mediations for Opioid Use Disorder Treatment[Internet]. Philadelphia, PA: Temple University Beasley School of Law Center for Public Health Law Research; 2020 August [cited 2024 October 1]. Available from: https:\/\/pdaps.org\/datasets\/medication-assisted-treatment-coverage-1580241551."},{"key":"1238_CR93","unstructured":"Congressional Research Service. Medicare Coverage of Medication Assisted Treatment (MAT) for Opioid Addiction (IF10875 Version 4)\u00a0[Internet]. Washington D.C.: Congressional Research Service; 2020 June 4 [cited 2024 October 6]. Available from: https:\/\/www.congress.gov\/crs-product\/IF10875."},{"key":"1238_CR94","unstructured":"Centers for Disease Control and Prevention. What You Can Do to Test for Fentanyl [Internet].\u00a0Atlanta, GA: Centers for Disease Control and Prevention; 2024 April []. Available from: https:\/\/www.cdc.gov\/stop-overdose\/safety\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/stopoverdose\/fentanyl\/fentanyl-test-strips.html. Accessed 20 Sept 2024."},{"key":"1238_CR95","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","volume":"63","author":"NC Peiper","year":"2019","unstructured":"Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019;63:122\u20138.","journal-title":"Int J Drug Policy"},{"key":"1238_CR96","doi-asserted-by":"publisher","first-page":"106529","DOI":"10.1016\/j.addbeh.2020.106529","volume":"110","author":"JN Park","year":"2020","unstructured":"Park JN, Tomko C, Silberzahn BE, Haney K, Marshall BDL, Sherman SG. A fentanyl test strip intervention to reduce overdose risk among female sex workers who use drugs in Baltimore: results from a pilot study. Addict Behav. 2020;110:106529.","journal-title":"Addict Behav"},{"issue":"8","key":"1238_CR97","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","volume":"112","author":"RS Alexander","year":"2022","unstructured":"Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112(8):1212\u20136.","journal-title":"Am J Public Health"},{"key":"1238_CR98","unstructured":"Krotulski AJ, Shinefield J, Teixeira da Silva D, Logan BK. Evaluation of Xylazine Test Strips (BTNX) for Drug Checking Purposes. [Internet]. Horsham, PA: Center for Forensic Science Research and Education; 2023 [cited 2024 April 17]. Available from: https:\/\/www.cfsre.org\/images\/content\/reports\/drug_checking\/Evaluation_of_BTNX_Xylazine_Test_Strips_for_Drug_Checking_230322.pdf."},{"key":"1238_CR99","unstructured":"Facher L. Newly available test strips can detect lethal \u2018tranq\u2019 in drug supply. STAT News. 2023 March 27. Available from:\u00a0https:\/\/www.statnews.com\/2023\/03\/27\/tranq-xylazine-test-strips-now-available\/."},{"key":"1238_CR100","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.dadr.2022.100074","volume":"4","author":"MK Reed","year":"2022","unstructured":"Reed MK, Imperato NS, Bowles JM, Salcedo VJ, Guth A, Rising KL. Perspectives of people in Philadelphia who use fentanyl\/heroin adulterated with the animal tranquilizer xylazine; Making a case for xylazine test strips. Drug Alcohol Depend Rep. 2022;4:100074.","journal-title":"Drug Alcohol Depend Rep"},{"key":"1238_CR101","doi-asserted-by":"publisher","first-page":"104154","DOI":"10.1016\/j.drugpo.2023.104154","volume":"120","author":"T Quijano","year":"2023","unstructured":"Quijano T, Crowell J, Eggert K, Clark K, Alexander M, Grau L, et al. Xylazine in the drug supply: emerging threats and lessons learned in areas with high levels of adulteration. Int J Drug Policy. 2023;120:104154.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1238_CR102","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/29767342241265181","volume":"46","author":"S Shrestha","year":"2025","unstructured":"Shrestha S, Cyr K, Hajinazarian G, Dillon J, Oh T, Pustz J, et al. Exploring xylazine awareness health impacts, and harm reduction strategies: findings from a multimethods study in Lowell Massachusetts. Subst Use Addctn J. 2025;46(2):291\u2013301.","journal-title":"Subst Use Addctn J"},{"key":"1238_CR103","doi-asserted-by":"publisher","first-page":"104206","DOI":"10.1016\/j.drugpo.2023.104206","volume":"121","author":"JN Park","year":"2023","unstructured":"Park JN, Tardif J, Thompson E, Rosen JG, Lira JAS, Green TC. A survey of North American drug checking services operating in 2022. Int J Drug Policy. 2023;121:104206.","journal-title":"Int J Drug Policy"},{"issue":"Supplement 6","key":"1238_CR104","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.1097\/PHH.0000000000001581","volume":"28","author":"TC Green","year":"2022","unstructured":"Green TC, Olson R, Jarczyk C, Erowid E, Thyssen S, Wightman R, et al. Implementation and uptake of the Massachusetts drug supply data stream: a statewide public health-public safety partnership drug checking program. J Public Health Manag Pract. 2022;28(Supplement 6):S347\u201354.","journal-title":"J Public Health Manag Pract"},{"key":"1238_CR105","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7217a2","author":"E Russell","year":"2023","unstructured":"Russell E. Rapid analysis of drugs: a pilot surveillance system to detect changes in the illicit drug supply to guide timely harm reduction responses\u2014eight syringe services programs, Maryland, November 2021\u2013August 2022. MMWR Morb Mortal Wkly Rep. 2023. https:\/\/doi.org\/10.15585\/mmwr.mm7217a2.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"1238_CR106","unstructured":"Expanding Nationwide Access to Test Strips Act, 118th Congress\u00a0(2023)."},{"key":"1238_CR107","unstructured":"STRIP Act, 118th Congress\u00a0(2023)."},{"key":"1238_CR108","unstructured":"Substance Abuse and Mental Health Services Administration. Federal Grantees May Now Use Funds to Purchase Fentanyl Test Strips [press release]. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2021 April 7. Available from: https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/media\/releases\/2021\/p0407-Fentanyl-Test-Strips.html. Accessed 23 April 2024."},{"key":"1238_CR109","unstructured":"Legislative Analysis and Public Policy Association. Drug Checking Equipment, Needles\/Syringes, and Drug Paraphernalia: Summary of State Laws[Internet]. Washington D.C.: Legislative Analysis and Public Policy Association; 2024 January [cited 2024 August 13]. Available from: https:\/\/legislativeanalysis.org\/wp-content\/uploads\/2024\/03\/FTS-and-Paraphernalia-Laws-January-2024-updated.pdf."},{"key":"1238_CR110","unstructured":"The Network for Public Health Law. Legality of Drug Checking Equipment in the United States: August 2024 UpdateThe Network for Public Health Law. Legality of Drug Checking Equipment in the United States: August 2024 Update [Internet]. Edina, MN: The Network for Public Health Law; 2024 August [cited 2024 September 13]. Available from: https:\/\/www.networkforphl.org\/wp-content\/uploads\/2024\/08\/2024-50-State-DCE-Fact-Sheet.pdf."},{"key":"1238_CR111","unstructured":"Legislative Analysis and Public Policy Association. Good Samaritan Fatal Overdose Prevention and Drug-induced Homicide: Summary of State Laws[Internet]. Washington D.C.: Legislative Analysis and Public Policy Association; 2024 April [cited 2025 March 24]. Available from: https:\/\/legislativeanalysis.org\/wp-content\/uploads\/2024\/05\/Good-Samaritan-Fatal-Overdose-Prevention-Summary-of-State-Laws.pdf."},{"issue":"15","key":"1238_CR112","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMp2207866","volume":"387","author":"CS Davis","year":"2022","unstructured":"Davis CS, Carr DH. Repealing state drug-paraphernalia laws \u2014 the need for federal leadership. N Engl J Med. 2022;387(15):1344\u20136.","journal-title":"N Engl J Med"},{"key":"1238_CR113","unstructured":"Singer JA, Heimowitz S. Drug Paraphernalia Laws Undermine Harm Reduction: To Reduce Overdoses and Disease, States Should Emulate Alaska, Policy Analysis No. 929[Internet]. Washington, D.C.: Cato Institute; 2022 June 7 [cited 2024 September 15]. Available from: https:\/\/www.cato.org\/sites\/cato.org\/files\/2023-08\/policy-analysis-960.pdf."},{"key":"1238_CR114","unstructured":"Legislative Analysis and Public Policy Association. Model Fentanyl\/Xylazine Test Strip and Other Drug Checking Equipment Act [Internet]. Washington, D.C.: Legislative Analysis and Public Policy Association; 2023 April [cited 2024 October 1]. Available from: https:\/\/legislativeanalysis.org\/wp-content\/uploads\/2023\/12\/Model-Fentanyl-Xylazine-Test-Strip-and-Other-Drug-Checking-Equipment-Act.pdf."},{"key":"1238_CR115","unstructured":"Carroll JJ, Green TC, Noonan RK. Evidence-based strategies for preventing opioid overdose: what\u2019s working in the United States: an introduction for public heath, law enforcement, local organizations, and others striving to serve their community[Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2018 [cited 2024 August 2] . Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/59393."},{"issue":"10","key":"1238_CR116","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3109\/15563650.2014.968657","volume":"52","author":"S Doyon","year":"2014","unstructured":"Doyon S, Aks SE, Schaeffer S. Expanding access to naloxone in the United States. Clin Toxicol. 2014;52(10):989\u201392.","journal-title":"Clin Toxicol"},{"issue":"8","key":"1238_CR117","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2021.306306","volume":"111","author":"A Razaghizad","year":"2021","unstructured":"Razaghizad A, Windle SB, Filion KB, Gore G, Kudrina I, Paraskevopoulos E, et al. The effect of overdose education and naloxone distribution: an umbrella review of systematic reviews. Am J Public Health. 2021;111(8):e1\u201312.","journal-title":"Am J Public Health"},{"key":"1238_CR118","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addbeh.2018.03.014","volume":"86","author":"C McClellan","year":"2018","unstructured":"McClellan C, Lambdin BH, Ali MM, Mutter R, Davis CS, Wheeler E, et al. Opioid-overdose laws association with opioid use and overdose mortality. Addict Behav. 2018;86:90\u20135.","journal-title":"Addict Behav"},{"key":"1238_CR119","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.drugpo.2019.07.031","volume":"75","author":"T Townsend","year":"2020","unstructured":"Townsend T, Blostein F, Doan T, Madson-Olson S, Galecki P, Hutton DW. Cost-effectiveness analysis of alternative naloxone distribution strategies: first responder and lay distribution in the United States. Int J Drug Policy. 2020;75:102536.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1238_CR120","doi-asserted-by":"publisher","first-page":"S180","DOI":"10.1016\/j.japh.2016.11.007","volume":"57","author":"C Davis","year":"2017","unstructured":"Davis C, Carr D. State legal innovations to encourage naloxone dispensing. J Am Pharm Assoc. 2017;57(2):S180\u20134.","journal-title":"J Am Pharm Assoc"},{"key":"1238_CR121","unstructured":"The Network for Public Health Law. Legal Interventions to Reduce Overdose Mortality: Naloxone Access Laws[Internet]. Edina, MN: The Network for Public Health Law; 2020 July 1 [cited 2024 May 14]. Available from: https:\/\/www.networkforphl.org\/wp-content\/uploads\/2021\/02\/50-State-Survey-Legal-Interventions-to-Reduce-Overdose-Mortality-Naloxone-Access-Laws.pdf."},{"key":"1238_CR122","unstructured":"SAFE Project. State Naloxone Access Rules and Resources [Internet]. Arlington, VA: SAFE Project; Date unknown [accessed 2024 October 8]. Available from: https:\/\/www.safeproject.us\/naloxone\/awareness-project\/state-rules\/."},{"key":"1238_CR123","unstructured":"Ryan E, Troop W, Chang A. The FDA approves the overdose-reversing drug Narcan for over-the-counter sales[Internet]. NPR. 2023 March 29.\u00a0Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-over-counter-naloxone-nasal-spray."},{"key":"1238_CR124","unstructured":"Addiction Policy Forum. Medicaid Access to Naloxone: A Look at State Policies to Removing Barriers to Accesshttps:\/\/www.addictionpolicy.org\/2024 [Internet]. Bethesda, MD: Addiction Policy Forum; 2024 March 4. https:\/\/www.addictionpolicy.org\/post\/medicaid-access-to-naloxone-a-look-at-state-policies-to-removing-barriers-to-access. Accessed 19 Sept 2024."},{"issue":"2","key":"1238_CR125","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/j.japh.2020.10.010","volume":"61","author":"J Contreras","year":"2021","unstructured":"Contreras J, Baus C, Brandt C, Witry M, Peters J, Evoy KE. Pharmacist counseling when dispensing naloxone by standing order: a secret shopper study of 4 chain pharmacies. J Am Pharm Assoc. 2021;61(2):e94\u20139.","journal-title":"J Am Pharm Assoc."},{"issue":"1","key":"1238_CR126","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/002204260203200113","volume":"32","author":"RS Broadhead","year":"2002","unstructured":"Broadhead RS, Kerr TH, Grund J-PC, Altice FL. Safer injection facilities in North America: their place in public policy and health initiatives. J Drug Issues. 2002;32(1):329\u201355.","journal-title":"J Drug Issues"},{"key":"1238_CR127","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.etdah.2022.100046","volume":"2","author":"SJ Dow-Fleisner","year":"2022","unstructured":"Dow-Fleisner SJ, Lomness A, Woolgar L. Impact of safe consumption facilities on individual and community outcomes: a scoping review of the past decade of research. Emerg Trends Drugs Addictn Health. 2022;2:100046.","journal-title":"Emerg Trends Drugs Addictn Health"},{"issue":"5","key":"1238_CR128","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.amepre.2021.04.017","volume":"61","author":"TW Levengood","year":"2021","unstructured":"Levengood TW, Yoon GH, Davoust MJ, Ogden SN, Marshall BDL, Cahill SR, et al. Supervised injection facilities as harm reduction: a systematic review. Am J Prev Med. 2021;61(5):738\u201349.","journal-title":"Am J Prev Med"},{"key":"1238_CR129","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.drugalcdep.2014.10.012","volume":"145","author":"C Potier","year":"2014","unstructured":"Potier C, Lapr\u00e9vote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48\u201368.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"1238_CR130","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jama.2019.0095","volume":"321","author":"LO Gostin","year":"2019","unstructured":"Gostin LO, Hodge JG, Gulinson CL. Supervised injection facilities: legal and policy reforms. JAMA. 2019;321(8):745\u20136.","journal-title":"JAMA"},{"issue":"7","key":"1238_CR131","doi-asserted-by":"publisher","first-page":"e2222149","DOI":"10.1001\/jamanetworkopen.2022.22149","volume":"5","author":"A Harocopos","year":"2022","unstructured":"Harocopos A, Gibson BE, Saha N, McRae MT, See K, Rivera S, et al. First 2 months of operation at first publicly recognized overdose prevention centers in US. JAMA Network Open. 2022;5(7):e2222149.","journal-title":"JAMA Network Open."},{"issue":"6","key":"1238_CR132","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMc2015435","volume":"383","author":"AH Kral","year":"2020","unstructured":"Kral AH, Lambdin BH, Wenger LD, Davidson PJ. Evaluation of an unsanctioned safe consumption site in the United States. N Engl J Med. 2020;383(6):589\u201390.","journal-title":"N Engl J Med"},{"issue":"6","key":"1238_CR133","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.amepre.2017.06.010","volume":"53","author":"AH Kral","year":"2017","unstructured":"Kral AH, Davidson PJ. Addressing the Nation\u2019s opioid epidemic: lessons from an unsanctioned supervised injection site in the US. Am J Prev Med. 2017;53(6):919\u201322.","journal-title":"Am J Prev Med."},{"issue":"11","key":"1238_CR134","doi-asserted-by":"publisher","first-page":"e2342228","DOI":"10.1001\/jamanetworkopen.2023.42228","volume":"6","author":"A Chalfin","year":"2023","unstructured":"Chalfin A, del Pozo B, Mitre-Becerril D. Overdose prevention centers, crime, and disorder in New York City. JAMA Netw Open. 2023;6(11):e2342228.","journal-title":"JAMA Netw Open."},{"issue":"15","key":"1238_CR135","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1007\/s11606-021-07312-4","volume":"37","author":"BH Lambdin","year":"2022","unstructured":"Lambdin BH, Davidson PJ, Browne EN, Suen LW, Wenger LD, Kral AH. Reduced emergency department visits and hospitalisation with use of an unsanctioned safe consumption site for injection drug use in the United States. J Gen Intern Med. 2022;37(15):3853\u201360.","journal-title":"J Gen Intern Med"},{"key":"1238_CR136","unstructured":"Comprehensive Drug Abuse Prevention and Control Act, (1970)."},{"key":"1238_CR137","unstructured":"Controlled Substance\u2014Maintaining Drug-Involved Premises, (2003)."},{"issue":"2","key":"1238_CR138","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2105\/AJPH.2006.103747","volume":"98","author":"L Beletsky","year":"2008","unstructured":"Beletsky L, Davis CS, Anderson E, Burris S. The law (and Politics) of safe injection facilities in the United States. Am J Public Health. 2008;98(2):231\u20137.","journal-title":"Am J Public Health"},{"key":"1238_CR139","unstructured":"Drug Policy Alliance. Overdose Prevention Centers: State of the Law [Internet]. New York, New York: Drug Policy Alliance; 2019 [cited 2025 March 30]. Available from: https:\/\/drugpolicy.org\/wp-content\/uploads\/2024\/04\/DPA-OPC-Legal-Risk-Analysis-Updated-December-2024.pdf."},{"key":"1238_CR140","unstructured":"United States v. Safehouse. United States Court of Appeals for the Third Circuit; 2021."},{"key":"1238_CR141","doi-asserted-by":"publisher","first-page":"103820","DOI":"10.1016\/j.drugpo.2022.103820","volume":"108","author":"LC Chambers","year":"2022","unstructured":"Chambers LC, Hallowell BD, Zang X, Rind DM, Guzauskas GF, Hansen RN, et al. The estimated costs and benefits of a hypothetical supervised consumption site in Providence, Rhode Island. Int J Drug Policy. 2022;108:103820.","journal-title":"Int J Drug Policy"},{"key":"1238_CR142","unstructured":"Buck K. First state-sanctioned overdose prevention center opens in Providence [press release]. NBC 10 News. 2024 December 10. Available from: https:\/\/turnto10.com\/news\/local\/ribbon-cutting-to-be-held-for-the-first-state-sanctioned-overdose-prevention-center-dec-10-2024."},{"issue":"1","key":"1238_CR143","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13722-023-00394-x","volume":"18","author":"A Jakubowski","year":"2023","unstructured":"Jakubowski A, Fowler S, Fox AD. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature. Addict Sci Clin Pract. 2023;18(1):40.","journal-title":"Addict Sci Clin Pract"},{"key":"1238_CR144","unstructured":"Center for Disease Control and Prevention. Syringe Service Programs [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2024 February 8. Available from: https:\/\/www.cdc.gov\/ssp\/index.html. Accessed 14 Aug 2024."},{"issue":"3","key":"1238_CR145","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0740-5472(00)00104-5","volume":"19","author":"H Hagan","year":"2000","unstructured":"Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000;19(3):247\u201352.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"1238_CR146","first-page":"137","volume":"27","author":"SC Ijioma","year":"2021","unstructured":"Ijioma SC, Pontinha VM, Holdford DA, Carroll NV. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree. J Manag Care Spec Pharm. 2021;27(2):137\u201346.","journal-title":"J Manag Care Spec Pharm"},{"key":"1238_CR147","unstructured":"Consolidated Appropriations Act, (2016)."},{"key":"1238_CR148","unstructured":"Castillo T. Congress Lifts the Ban on Federal Funding for Syringe Exchange Programs. Huffington Post. 2016 January 20. Available from: https:\/\/www.huffpost.com\/entry\/congress-lifts-the-ban-on_b_9032362."},{"key":"1238_CR149","unstructured":"North American Syringe Exchange Network. Harm Reduction Locations [Internet]. Tacoma, WA: North American Syringe Exchange Network. 2025. Available from: https:\/\/nasen.org\/?go=process. Accessed 4 April 2025."},{"key":"1238_CR150","unstructured":"Consolidated Appropriations Act, (2018)."},{"key":"1238_CR151","unstructured":"Javed Z, Burk K, Facente S, Pegram L, Ali A, Asher A. Syringe services programs: a technical package of effective strategies and approaches for planning, design, and implementation [Internet]. Washington D.C.: US Department of Health and Human Services, National Center for HIV\/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention; 2020 [cited 2025 April 17]. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/105304."},{"issue":"5","key":"1238_CR152","doi-asserted-by":"publisher","first-page":"e048478","DOI":"10.1136\/bmjopen-2020-048478","volume":"12","author":"EO Murchu","year":"2022","unstructured":"Murchu EO, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12(5):e048478.","journal-title":"BMJ Open"},{"key":"1238_CR153","unstructured":"U.S. Preventive Services Task Force. Final Recommendation Statement- Prevention of Acquisition of HIV: Preexposure Prophylaxis[Internet]. Rockville, MD: U.S. Preventive Services Task Force; 2023 August 22 [cited 2025 April 24]. Available from: https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis#fullrecommendationstart."},{"key":"1238_CR154","unstructured":"HIV+Hepatitis Policy Institute. HIV+Hep estimates HIV cases averted & cost savings due to long-acting PrEP [press release]. 2024 February 14 [cited 2025 April 25]. Available from: https:\/\/hivhep.org\/press-releases\/hivhep-estimates-hiv-cases-averted-cost-savings-due-to-long-acting-prep\/."},{"key":"1238_CR155","unstructured":"Moore K. Feds issue new guidance on Medicare and private payer coverage of PrEP for HIV [Internet]. Leawood, KS: American Academy of Family Physicians; 2024 October 25. Available from: https:\/\/www.aafp.org\/pubs\/fpm\/blogs\/gettingpaid\/entry\/fed-prep-guidance.html. Accessed 24 April 2025."},{"issue":"1","key":"1238_CR156","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/JNC.0000000000000275","volume":"33","author":"N Carnes","year":"2022","unstructured":"Carnes N, Zhang J, Gelaude D, Y-lA Huang, Mizuno Y, Hoover KW. Restricting access: a secondary analysis of scope of practice laws and pre-exposure prophylaxis prescribing in the United States 2017. J Assoc Nurses AIDS Care. 2022;33(1):89\u201397.","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"1","key":"1238_CR157","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1089\/heq.2021.0113","volume":"6","author":"S Salvant Valentine","year":"2022","unstructured":"Salvant Valentine S, Carnes N, Caldwell J, Gelaude D, Taylor R. Mapping nurse practitioners\u2019 scope of practice laws: a resource for evaluating pre-exposure prophylaxis prescriptions. Health Equity. 2022;6(1):27\u201331.","journal-title":"Health Equity"},{"key":"1238_CR158","unstructured":"Center for Disease Control and Prevention. Preventing HIV with PrEP [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2024 February. Available from: https:\/\/www.cdc.gov\/hiv\/prevention\/prep.html. Accessed 18 Sept 2024."},{"key":"1238_CR159","unstructured":"Sobel L, Salganicoff A, Felix M. ACA Preventive Services Are Back at the Supreme Court: Kennedy v. Braidwood[Internet]. San Francisco, CA: Kaiser Family Institute; 2025 April 15 [cited 2025 April 25]. Available from: https:\/\/www.kff.org\/womens-health-policy\/issue-brief\/aca-preventive-services-supreme-court-kennedy-braidwood\/."},{"key":"1238_CR160","doi-asserted-by":"publisher","first-page":"109336","DOI":"10.1016\/j.drugalcdep.2022.109336","volume":"232","author":"HK Knudsen","year":"2022","unstructured":"Knudsen HK, Hartman J, Walsh SL. The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States. Drug Alcohol Depend. 2022;232:109336.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1238_CR161","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamainternmed.2020.0473","volume":"180","author":"H Wen","year":"2020","unstructured":"Wen H, Soni A, Hollingsworth A, Freedman S, Benitez J, Simon K, et al. Association between Medicaid expansion and rates of opioid-related hospital use. JAMA Intern Med. 2020;180(5):753\u20139.","journal-title":"JAMA Intern Med"},{"key":"1238_CR162","unstructured":"Broaddus M, Bailey P, Aron-Dine A. Medicaid Expansion Dramatically Increased Coverage for People with Opioid-Use Disorders, Latest Data Show[Internet]. Washington D.C.: Center on Budget and Policy Priorities; 2018 February [cited 2024 October 1]. Available from: https:\/\/www.cbpp.org\/sites\/default\/files\/atoms\/files\/2-28-18health.pdf."},{"issue":"1","key":"1238_CR163","doi-asserted-by":"publisher","first-page":"e1919066","DOI":"10.1001\/jamanetworkopen.2019.19066","volume":"3","author":"N Kravitz-Wirtz","year":"2020","unstructured":"Kravitz-Wirtz N, Davis CS, Ponicki WR, Rivera-Aguirre A, Marshall BDL, Martins SS, et al. Association of medicaid expansion with opioid overdose mortality in the United States. JAMA Netw Open. 2020;3(1):e1919066.","journal-title":"JAMA Netw Open."},{"key":"1238_CR164","unstructured":"Kaiser Family Foundation. Status of State Medicaid Expansion Decisions: Interactive Map 2025 [Internet]. San Francisco, CA: Kaiser Family Foundation; 2025 February. Available from: https:\/\/www.kff.org\/affordable-care-act\/issue-brief\/status-of-state-medicaid-expansion-decisions-interactive-map\/. Accessed 17 April 2025."},{"key":"1238_CR165","unstructured":"Cohen C, Hern\u00e1ndez-Delgado H, Robles-Fradet A. Medicaid section 1115 waivers for substance use disorders: a review[Internet]. Washington D.C.: National Health Law Program; 2021 June [cited 2024 October 1]. Available from: https:\/\/healthlaw.org\/wp-content\/uploads\/2021\/06\/FINAL_Medicaid-1115-Waivers-for-SUD-updated.pdf."},{"key":"1238_CR166","unstructured":"Kaiser Family Foundation. Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State[Internet]. San Francisco, CA: Kaiser Family Institute; 2024 October 2. Available from:\u00a0https:\/\/www.kff.org\/medicaid\/issue-brief\/medicaid-waiver-tracker-approved-and-pending-section-1115-waivers-by-state\/. Accessed 8 Oct 2024."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01238-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01238-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01238-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T19:02:35Z","timestamp":1749409355000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01238-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":166,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01238-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,8]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}